Brokerages Expect Prothena Corp (PRTA) Will Post Earnings of -$1.24 Per Share
Wall Street brokerages expect Prothena Corp (NASDAQ:PRTA) to announce earnings per share (EPS) of ($1.24) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Prothena’s earnings, with estimates ranging from ($1.49) to ($0.83). Prothena reported earnings of ($0.99) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 25.3%. The business is expected to report its next earnings results on Tuesday, May 8th.
According to Zacks, analysts expect that Prothena will report full year earnings of ($5.35) per share for the current fiscal year, with EPS estimates ranging from ($6.51) to ($2.87). For the next financial year, analysts forecast that the firm will post earnings of ($4.10) per share, with EPS estimates ranging from ($5.84) to ($1.81). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Prothena.
Prothena (NASDAQ:PRTA) last announced its earnings results on Wednesday, February 14th. The biotechnology company reported ($1.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.48) by $0.24. The company had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.27 million. Prothena had a negative net margin of 556.84% and a negative return on equity of 33.37%. The firm’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.41) earnings per share.
Several institutional investors and hedge funds have recently bought and sold shares of the business. Delek Group Ltd. bought a new position in shares of Prothena in the fourth quarter worth approximately $1,123,000. Platinum Investment Management Ltd. boosted its position in shares of Prothena by 13.5% during the fourth quarter. Platinum Investment Management Ltd. now owns 70,400 shares of the biotechnology company’s stock worth $2,639,000 after acquiring an additional 8,400 shares during the last quarter. Millennium Management LLC bought a new position in shares of Prothena during the fourth quarter worth $338,000. HBK Investments L P bought a new position in shares of Prothena during the fourth quarter worth $213,000. Finally, Two Sigma Investments LP bought a new position in shares of Prothena during the fourth quarter worth $472,000.
NASDAQ PRTA traded up $0.28 during trading hours on Wednesday, hitting $38.25. 30,522 shares of the company’s stock traded hands, compared to its average volume of 540,256. The firm has a market capitalization of $1,464.29, a price-to-earnings ratio of -9.41 and a beta of 2.70. Prothena has a 52 week low of $27.19 and a 52 week high of $70.00.
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.